A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
Study Details
Study Description
Brief Summary
The primary objectives of this study are to identify the recommended dose for expansion (RDE) (and recommended schedule) and/or maximum tolerated dose (MTD), and to characterize the safety and the tolerability of ADCT-901.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part 1: Dose Escalation In Part 1 (dose escalation) participants with selected advanced solid tumors will receive escalating doses of ADCT-901 as monotherapy. Participants can receive ADCT-901 until disease progression, adverse event (AE), or other discontinuation criteria, whichever occurs first. |
Drug: ADCT-901
Intravenous infusion
|
| Experimental: Part 2: Dose Expansion In Part 2 (dose expansion), participants will receive ADCT-901 monotherapy at the dose identified as the RDE/MTD in Part 1 (dose escalation). Participants will be split into two groups: Group 1: An indication for which ADCT-901 showed in Part 1 to have preliminary activity. Group 2: A group of participants with Part 1 indications, except for the one selected in Group 1 of Part 2. No more than 30% of participants with the same indication are allowed in this basket group. Participants can receive ADCT-901 until disease progression, AE, or other discontinuation criteria, whichever occurs first. |
Drug: ADCT-901
Intravenous infusion
|
Outcome Measures
Primary Outcome Measures
- Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) [Up to approximately 3.5 years]
Adverse events (AEs) and serious adverse events (SAEs) were defined as any untoward medical occurrence in participants whether or not considered related to the investigational medicinal product. Any clinically significant changes in vital signs, laboratory values, 12-lead electrocardiogram (ECG) and Eastern Cooperative Oncology Group (ECOG) performance status results will be recorded as AEs and SAEs.
- Number of Participants Who Experience a Dose Interruption [Up to approximately 3.5 years]
- Number of Participants Who Experience a Dose Reduction [Up to approximately 3.5 years]
- Number of Participants Who Experience a Dose Limiting Toxicity (DLT) During the Dose-Escalation Phase [Day 1 to Day 21]
Secondary Outcome Measures
- Overall Response Rate (ORR) [Up to approximately 3.5 years]
- Duration of Response (DOR) [Up to approximately 3.5 years]
- Progression-Free Survival (PFS) [Up to approximately 3.5 years]
- Overall Survival (OS) [Up to approximately 3.5 years]
- Maximum Concentration (Cmax) of ADCT-901 Total Antibody, Pyrrolobenzodiazepine (PBD)-Conjugated Antibody, and Unconjugated Warhead SG3199 in Serum [Up to approximately 3.5 years]
- Time to Maximum Concentration (Tmax) of ADCT-901 Total Antibody, Pyrrolobenzodiazepine (PBD)-Conjugated Antibody, and Unconjugated Warhead SG3199 in Serum [Up to approximately 3.5 years]
- Area Under the Concentration-Time Curve From Time Zero to the End of the Dosing Interval (AUClast) of ADCT-901 Total Antibody, Pyrrolobenzodiazepine (PBD)-Conjugated Antibody, and Unconjugated Warhead SG3199 in Serum [Up to approximately 3.5 years]
- Area Under the Concentration-Time Curve From Time Zero to the End of the Dosing Interval (AUCtau) of ADCT-901 Total Antibody, Pyrrolobenzodiazepine (PBD)-Conjugated Antibody, and Unconjugated Warhead SG3199 in Serum [Up to approximately 3.5 years]
- Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of ADCT-901 Total Antibody, Pyrrolobenzodiazepine (PBD)-Conjugated Antibody, and Unconjugated Warhead SG3199 in Serum [Up to approximately 3.5 years]
- Apparent Terminal Elimination Half-Life (Thalf) of ADCT-901 Total Antibody, Pyrrolobenzodiazepine (PBD)-Conjugated Antibody, and Unconjugated Warhead SG3199 in Serum [Up to approximately 3.5 years]
- Apparent Clearance (CL) of ADCT-901 Total Antibody, Pyrrolobenzodiazepine (PBD)-Conjugated Antibody, and Unconjugated Warhead SG3199 in Serum [Up to approximately 3.5 years]
- Apparent Volume of Distribution (Vss) of ADCT-901 Total Antibody, Pyrrolobenzodiazepine (PBD)-Conjugated Antibody, and Unconjugated Warhead SG3199 in Serum [Up to approximately 3.5 years]
- Accumulation Index (AI) of ADCT-901 Total Antibody, Pyrrolobenzodiazepine (PBD)-Conjugated Antibody, and Unconjugated Warhead SG3199 in Serum [Up to approximately 3.5 years]
- Number of Participants with an Anti-drug Antibody (ADA) Response to ADCT-901 [Up to approximately 3.5 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Pathologic diagnosis of selected solid tumor malignancy that is locally advanced or metastatic at time of Screening: cholangiocarcinoma, ovarian/fallopian tube cancers, prostate cancer, renal cell carcinoma, and triple negative breast cancer (TNBC).
Note: Histologic variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate are permitted.
-
Participants who are refractory to or intolerant to existing therapy(ies) known to provide clinical benefit for their condition per Investigator judgment.
-
Participants with measurable disease as determined by Response Evaluation Criteria In
Solid Tumors (RECIST) v1.1:
Note 1: Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, that can be evaluated by cross sectional imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) can be considered as measurable lesions only if the soft tissue component meets the definition of measurability per RECIST v1.1.
Note 2: Prostate cancer participants without measurable lesions will be accepted, with evidence of bone metastatic disease on radiographic examination, whether from bone scan or other imaging modality, and prostate specific antigen (PSA) ≥2.0 ng/mL.
Exclusion Criteria:
- History of recent infection (requiring intravenous [IV] antibiotics, IV antiviral or IV antifungal treatment within 4 weeks of cycle 1, day 1 [C1D1]).
Note: A pathogen-directed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test (polymerase chain reaction [PCR]) is mandatory and must be negative before initiating study treatment (tests to be performed 3 days or less prior to dosing on C1D1; an additional 2 days are allowed in the event of logistical issues for receiving the results on time).
-
Symptomatic central nervous system (CNS) metastases or evidence of leptomeningeal disease (brain MRI or previously documented cerebrospinal fluid cytology). Previously treated asymptomatic CNS metastases are permitted provided that the last treatment (systemic anticancer therapy and/or local radiotherapy) was completed ≥4 weeks prior to C1D1 except usage of low dose of steroids on a taper (i.e., up to 10 mg prednisone or equivalent on Day 1 and consecutive days is permissible if being tapered down). Participants with discrete dural metastases are eligible.
-
Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or any serosal effusion that is either requiring drainage or associated with shortness of breath).
-
Active diarrhea ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or a medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease).
-
Active or clinically significant ocular disease including ocular surface disease at baseline. An ocular evaluation is to be confirmed by an ophthalmologist at screening. Participants with any prior episode of cicatricial conjunctivitis (as evaluated by the ophthalmologist) are ineligible.
Note 1: Cataract is not considered active ocular surface disease for this protocol. Mild dry eye syndrome or blepharitis managed with artificial tear drops, without injection or epithelial changes, is allowed.
- Use of any other experimental medication within 14 days prior to start of study drug (C1D1).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sarah Cannon at HealthONE | Denver | Colorado | United States | 80218 |
| 2 | Yale Cancer Center | New Haven | Connecticut | United States | 06520 |
| 3 | Emory University, Winship Cancer Institute | Atlanta | Georgia | United States | 30322 |
| 4 | Northwestern University | Chicago | Illinois | United States | 60611 |
| 5 | University Hospitals of Cleveland Medical Center (UHCMC) | Cleveland | Ohio | United States | 44106 |
| 6 | Sarah Cannon at University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | United States | 73104 |
| 7 | NEXT Oncology | San Antonio | Texas | United States | 78229 |
Sponsors and Collaborators
- ADC Therapeutics S.A.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ADCT-901-101
- 2021-002292-19